Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
Xuanwu Hospital, Beijing
6,000 participants
Aug 15, 2025
OBSERVATIONAL
Conditions
Summary
The investigators propose a stepwise screening approach. The first step involves rapid digital pre-screening of cognitive function through three components: the SCD-9 questionnaire to capture subjective cognitive complaints, a digital cognitive assessment to evaluate objective performance, and a predictive model to estimate future dementia risk in cognitively normal individuals. The second step confirms the presence of AD pathology using blood-based biomarkers, with a head-to-head comparison of multiple novel candidates to identify those with the greatest diagnostic utility.
Eligibility
Inclusion Criteria6
- adults aged 50 and above;
- living in community for at least one year and having established medical records;
- denying a history of cognitive disorders (mild cognitive impairment, dementia, Alzheimer's disease, etc.) and the use of anti-dementia drugs (cholinesterase inhibitors or memantine, etc.);
- agreeing to participate in the study;
- individual or their relatives can communicate normally in Chinese.
- high-risk groups for dementia（including:1. Complaints of cognitive decline and/or statements by the informant;2. History of AD in first-degree relatives;3. Known ApoE e4 carrier.）
Exclusion Criteria2
- Self-reporting or confirmation through inquiry indicates the presence of severe mental disorders, such as bipolar disorder or schizophrenia, etc.
- Having a disease that makes it impossible to complete the cognitive assessment.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07284264